Gilead delivered healthy earnings as a result of the huge sales of its hepatitis C drug Solvaldi. David Nelson, Chief Strategist at Belpointe Asset Management believes the stock could continue to move higher. Even though insurers are pushing back about the price of the treatment, Gilead wants to recoup the cost of research to develop the drug. Plus, taking the drug for a one time treatment prevents more expensive consequences of not taking the drug, like liver disease.

More from Video

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home